t
On 15 September 2023, Tissue Regenix Group plc announced that Non-Executive Director Brian Phillips bought 6,773 Ordinary Shares at 54 pence per share, totaling £3,657.42. As a result, Brian Phillips holds 160,000 Ordinary Shares, representing 0.23% of the Company's total issued share capital. Separately, the Company's Nominated Adviser and Sole Broker changed its name to Cavendish Capital Markets Limited.
| Date | 15 Sept 2023 |
| Time | 16:30:00 |
| Category | Director/PDMR dealings |
| ID | 6628M |
Tissue Regenix Group plc
("Tissue Regenix", the "Company" or "the Group")
Director/PDMR Shareholding
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that on 15 September 2023, Brian Phillips, Non-Executive Director, bought 6,773 Ordinary Shares in the Group at a price of 54 pence per share for a total consideration of £3,657.42.
As a result, Brian Phillips holds 160,000 Ordinary Shares in the Company representing 0.23% of the total issued share capital.
Change of Name of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser and Sole Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger.
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
|
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance |
|
|
|
Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings/Lianne Applegarth |
||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Brian Phillips |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Tissue Regenix Group plc |
|||
|
b)
|
LEI
|
213800PNOD5UHQUFJI36 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1p each |
|||
|
|
|
||||
|
Identification code |
GB00B5SGVL29 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
0.54 |
6,773 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
6,773 |
||||
|
|
|
||||
|
- Price |
£3,657.42 |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
15 September 2023 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM Market |
|||